GlassScriptPhysician profile
Mitchell Ian Sorsby
NPI 1154375939
$945,211.03
in general payments reported to CMS, 2019-2025
62 companies · $77K in 2025
The $77K reported for 2025 was more than what 97% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $305K · 2020: $78K · 2021: $100K · 2022: $176K · 2023: $111K · 2024: $99K · 2025: $77K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $259K · Travel and Lodging: $19K · Food and Beverage: $8,015 · Education: $42.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $259,309.64 |
| Travel and Lodging | $18,773.88 |
| Food and Beverage | $8,014.69 |
| Education | $42.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $454,676.36 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $175,449.15 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $90,701.43 | 2019-2025 | |
| Radius Health, INC. | $81,170.68 | 2019-2024 | Tymlos |
| Amarin Pharma, INC. | $27,476.54 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $23,266.19 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $18,792.66 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $16,801.47 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13,895.45 | 2019-2024 | Jardiance |
| Dexcom, INC. | $11,017.52 | 2019-2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $6,485.82 | 2019-2023 | Cycloset |
| Abbott Laboratories | $5,587.48 | 2019-2025 | Freestyle Libre 3, Proclaim, Freestyle Libre 2 |
| Tandem Diabetes Care, INC. | $4,716.88 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Mannkind Corporation | $4,702.56 | 2019-2023 | Afrezza |
| Vivus LLC | $3,720.89 | 2019-2024 | Qsymia |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,075.60 | 2019-2025 | Evenity, Prolia, Tepezza |
| Abbvie INC. | $741.13 | 2019-2025 | Synthroid |
| Insulet Corporation | $699.29 | 2019-2025 | Omnipod, Omnipod |
| Alexion Pharmaceuticals, INC. | $420.37 | 2019-2025 | Strensiq |
| Xeris Pharmaceuticals, INC. | $373.97 | 2020-2024 | Gvoke Hypopen, Recorlev |
| Corcept Therapeutics | $337.73 | 2019-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $329.44 | 2021-2025 | |
| Medtronic, INC. | $322.38 | 2022-2025 | Minimed 780g, Inpen Smart Insulin Delivery System, Venaseal |
| Esperion Therapeutics, INC. | $266.23 | 2020-2021 | |
| Amneal Pharmaceuticals LLC | $226.11 | 2019-2024 | Unithroid |
| Horizon Therapeutics Plc | $190.16 | 2022-2023 | Tepezza |
| Ibsa Pharma INC. | $171.91 | 2019-2025 | Tirosint, Licart, Licart |
| Companion Medical, INC. | $171.84 | 2019-2020 | |
| Gilead Sciences, INC. | $113.40 | 2019 | |
| Eton Pharmaceuticals, INC. | $112.15 | 2020-2021 | |
| Cequr Corporation | $100.26 | 2022-2024 | Cequr Simplicity |
| Valeritas, INC. | $91.82 | 2019 | |
| Pfizer INC. | $86.89 | 2019-2023 | |
| Zealand Pharma US, INC. | $84.29 | 2020-2021 | |
| Antares Pharma, INC. | $66.84 | 2020-2025 | Xyosted |
| Kowa Pharmaceuticals America, INC. | $66.31 | 2019-2022 | |
| Shire North American Group INC | $64.78 | 2019 | |
| Rhythm Pharmaceuticals, INC. | $53.00 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $40.70 | 2021-2022 | |
| Intuity Medical INC | $38.99 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Recordati_rare_diseases_inc. | $34.90 | 2025 | Isturisa |
| Astellas Pharma US INC | $34.68 | 2024-2025 | Veozah |
| Ascensia Diabetes Care US INC. | $29.31 | 2021 | |
| Althera Pharmaceuticals LLC | $28.69 | 2021-2022 | |
| Madrigal Pharmaceuticals | $28.52 | 2025 | Rezdiffra |
| Medtronic Minimed, INC. | $26.36 | 2019-2020 | |
| Tolmar Pharmaceuticals, INC. | $25.05 | 2022 | |
| Acerus Pharmaceuticals Corporation | $24.93 | 2020-2021 | |
| Ascendis Pharma Endocrinology INC | $24.43 | 2023 | |
| Beta Bionics, INC. | $24.33 | 2023-2024 | Ilet Bionic Pancreas |
| Aytu Biopharma, INC. | $23.80 | 2019 | |
| Vifor Pharma, INC. | $22.09 | 2019 | |
| Sun Pharmaceutical Industries INC. | $21.88 | 2020 | |
| Amryt Pharma Holdings LTD | $21.34 | 2022 | |
| Alvogen INC | $21.29 | 2023 | Teriparatide |
| Kyowa Kirin, INC. | $19.49 | 2024 | Crysvita |
| Amphastar Pharmaceuticals, INC. | $18.52 | 2024 | |
| Acella Pharmaceuticals, LLC | $16.97 | 2023 | NP Thyroid 60 |
| Agios Pharmaceuticals, INC. | $16.56 | 2025 | Pyrukynd |
| Becton, Dickinson and Company | $16.28 | 2021 | |
| Lifescan, INC. | $13.82 | 2023 | |
| Arbor Pharmaceuticals, INC. | $11.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Sorsby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.